

To: Sarvamangala Devi
Location: REM 3C18
Art Unit: 1645
Wednesday, May 12, 2004

Case Serial Number: 09/853367

From: Beverly Shears
Location: Remsen Bldg.
RM 1A54
Phone: 571-272-2528

beverly.shears@uspto.gov

Search Notes

Shears, Beverly

From: Devi, Sarvamangala
Sent: Thursday, May 06, 2004 2:28 PM
To: Shears, Beverly
Subject: 09/853,367

Beverly:

Would you please perform a text search for the claim below and an inventors' name search in application 09/853,367?

1. (currently amended) An immunogenic conjugate comprising hyaluronic acid (hyaluronate) moieties covalently bound to an immunologically- and physiologically suitable polypeptide selected from the group consisting of: a bacterial toxin toxoid; and bacterial or viral polypeptide carrier, wherein greater than about 50% of the hyaluronic acid moieties possess a non-reducing terminal glucuronic acid and/or unsaturated glucuronic acid residue, wherein the hyaluronic acid moieties are low molecular weight hyaluronic acid with a molecular weight of from about 600 daltons to about 400 kilodaltons, and said immunogenic conjugate induces an immune response to epitopes comprising the non-reducing terminal glucuronic acid or unsaturated glucuronic acid residues of said hyaluronic acid moieties.

Inventors: Francis Michon; Samuel Moore; Maryline Laude-Sharp; Milan Blake

Thank.

S. DEVI, Ph.D.
AU 1645
Rems - 3C18



Date completed: 05-11-04
Searcher: Beverly e 2528
Terminal time: _____
Elapsed time: _____
CPU time: _____

Search Site
____ STIC
____ CM-1
____ Pre-S
Type of Search

Vendors
____ IG
____ STN
____ Dialog

FOR OFFICIAL USE ONLY
ACCESS DB # _____

68993

PLEASE PRINT CLEARLY
Location (Bldg/Room#): CM1-7E15
Mail box CM1-7E12

Scientific and Technical Information Center

SEARCH REQUEST FORM

Date: 06.17.02 Requester's Full Name: _____ Examiner #: S. DEVI
Art Unit: 1645 Phone (308) 9347 Serial Number: 09/853,367
Results Format Preferred (circle): PAPER DISK E-MAIL

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____
Inventors (please provide full names): FRANCIS MICHON; SAMUEL MOORE; MILAN BLAKE
MARYLINE LAUDE-SHARP

Earliest Priority Date: 05-11-01

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the selected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known.

For Sequence Searches Only Please include all pertinent information (parent, grandchild, divisional, or issued patent numbers) along with appropriate serial number.

Please ask MS. BEVERLY SHEARS to perform this search.

Please see attached claims with key words highlighted and/or Examples and synonyms provided.

Please include the following databases: Embase, Medline, Biosis, CA (Dialog 50), JAPIO, JICTEplus, Dialog 35, 65, 77, 144, 256, 266, 440, 348, 357, 113, 129, 130, 156 and 60.

Please perform an inventor's name search.

Structure Search (enclosed)

Thank you. ☺

Point of Contact:
Beverly Shears
Technical Info. Specialist
CM1 1E05 Tel: 308-4994

Please return the attached claims and this search request form along with the search reports.

Hyaluron? (don) (conjugat? or couple? or link? or bound)

(Hyaluronate or group A or group C streptococci?
capsular polysaccharide?)

We claim:



1. An immunogenic conjugate molecule comprising hyaluronic acid covalently bound to an immunologically-suitable polypeptide carrier. (protein carrier)

2. The immunogenic conjugate according to claim 1, wherein greater than about 50% of the hyaluronic acid molecules possess a nonreducing terminal glucuronic acid and/or unsaturated glucuronic acid residue.

3. The immunogenic conjugate according to claim 2, wherein the hyaluronic acid is a low molecular weight hyaluronic acid with a molecular weight of about 400 Kd or less and a molecular weight of about 600 daltons or more.

4. The immunogenic conjugate according to claim 3, wherein at least 90% or greater of the low molecular weight hyaluronic acid fragments possess a nonreducing terminal glucuronic acid and/or unsaturated glucuronic acid residue.

